Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis

Phase II study of everolimus in metastatic urothelial cancer

(2013) Matthew I. Milowsky et al.   BJU INTERNATIONAL

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

(2013) John J Bissler et al.   LANCET

Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data

(2013) Wei-Xiang Qi et al.   PLoS One

Oncology; Everolimus: A New Treatment Option for Advanced Pancreatic Neuroendocrine Tumors

(2012) Lisa A Thompson et al.   ANNALS OF PHARMACOTHERAPY

Targeting mTOR in mantle cell lymphoma: Current and future directions

(2012) Sonali M. Smith   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

(2012) K. A. Margolin et al.   CLINICAL CANCER RESEARCH

Phase II Study of the Safety and Efficacy of Temsirolimus in East Asian Patients with Advanced Renal Cell Carcinoma†

(2012) Yan Sun et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

(2012) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

The mTOR Pathway in Lung Cancer and Implications for Therapy and Biomarker Analysis

(2012) Simon Ekman et al.   Journal of Thoracic Oncology

The Risk for Anemia with Targeted Therapies for Solid Tumors

(2012) S. Barni et al.   ONCOLOGIST

A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas

(2011) Scott Okuno et al.   CANCER

Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies

(2011) Nushmia Z. Khokhar et al.   CURRENT OPINION IN ONCOLOGY

Mammalian Target of Rapamycin (mTOR) Inhibitors

(2011) Sofia Sofroniadou et al.   DRUG SAFETY

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

The Role of Vandetanib in the Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Four Randomized Controlled Trials

(2011) Wei-Xiang Qi et al.   LUNG

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting mTOR in renal cell carcinoma

(2010) Gary R. Hudes   CANCER

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

(2010) Brian M. Slomovitz et al.   CANCER

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

(2010) A. Tarhini et al.   CLINICAL CANCER RESEARCH

Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer

(2010) Toshihiko Doi et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials

(2010) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies

(2009) David T. Teachey et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

(2009) Robert J. Amato et al.   CANCER

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

(2009) Susan L. Ellard et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

(2009) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE

Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer

(2008) Brian M. Wolpin et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET